In China, the third-generation EGFR-TKI, osimertinib, is standard treatment for patients with advanced EGFR T790M-mutated NSCLC who have been pre-treated with early-generation EGFR-TKIs (gefitinib, erlotinib, icotinib, or afatinib) (12). Here, EGFR is linked to non-small cell lung carcinoma.